Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
Growth factors provide powerful mitogenic and survival signals to breast cancer cells and it is therefore not surprising that they are able to subvert inhibitory responses to anti-hormonal drugs. In this review we discuss several mechanisms by which this may be achieved and expand our observations to encompass recently emerging anti-growth factor treatments. The information presented is underpinned by inhibitor studies that show the targeting of such mechanisms in advance of anti-hormone or anti-growth factor resistance development is able to substantially delay this event, thus pointing the way forward to intelligent combination therapies relevant to the future management of breast cancer.
Nicholson
R I
RI
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Cardiff, UK. NicholsonRI@cardiff.ac.uk
Hutcheson
I R
IR
Jones
H E
HE
Hiscox
S E
SE
Giles
M
M
Taylor
K M
KM
Gee
J M W
JM
D001943:Breast Neoplasms / Q000503:physiopathology*; D066246:ErbB Receptors / Q000502:physiology; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology*; D011960:Receptors, Estrogen / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*
D036341:Intercellular Signaling Peptides and Proteins; D011960:Receptors, Estrogen; D066246:ErbB Receptors